What were the primary drivers of BDX's revenue growth in this quarter?

BDX experienced a 10% revenue increase driven by strong performance across its Medical, Diagnostics, and Biosciences segments. Key growth areas included Diabetes Care and Pharmaceutical Systems within Medical, strong flu diagnostic test sales in Diagnostics, and increased demand for research instruments and reagents in Biosciences. The company also benefited from the continued transition to safety-engineered devices in both U.S. and international markets.

How is the planned acquisition of GeneOhm Sciences expected to impact the company?

BDX agreed to acquire GeneOhm Sciences for approximately $230 million to enhance its molecular diagnostics capabilities. While the acquisition is expected to close in the fiscal quarter ending March 31, 2006, it is projected to be dilutive to earnings per share by an estimated 1 cent in the second quarter and 7 cents for the full fiscal year 2006. Additionally, an in-process R&D charge is expected upon closing, estimated to impact diluted EPS by 20-25 cents in fiscal year 2006.

What is the trend in share-based compensation, and how does it affect the company's profitability?

Share-based compensation expense saw a substantial increase, rising to $34.6 million from $11.6 million in the prior year's quarter. This increase is primarily attributed to new grant structures under the 2004 Plan, including stock appreciation rights (SARs) and a shortened requisite service period for certain awards. This higher expense is impacting operating income and net income, and the company expects to recognize approximately $182.2 million in unrecognized compensation expense over the next 2.5 years.

How is the company managing its liquidity and capital resources?

BDX generated $171 million in net cash from continuing operating activities during the quarter, which is its primary source of funds. Capital expenditures were $64 million, and the company expects total capital spending for fiscal 2006 to be in the $400 million range. The debt-to-capitalization ratio increased slightly to 28.0% from 27.3%. The company has a commercial paper borrowing program and a $900 million syndicated credit facility to support its financing needs.

BDX 10-Q Quarterly Report Q1 FY2006 — Revenue, Net Income, EPS

Summary

Becton Dickinson & Co. (BDX) reported solid financial results for the fiscal first quarter ended December 31, 2005. The company demonstrated robust revenue growth of 10% year-over-year, reaching $1.41 billion, driven by strong performance across its Medical, Diagnostics, and Biosciences segments. This top-line growth translated into a significant increase in operating income and net income, with diluted earnings per share from continuing operations rising to $0.85 from $0.74 in the prior year period. The company maintained a strong balance sheet with a healthy cash position and managed its debt effectively, although short-term debt saw an increase. Management highlighted strategic initiatives focused on revenue growth through innovative products and operational efficiency, which appear to be yielding positive results. Looking ahead, BDX announced a significant development with the agreement to acquire GeneOhm Sciences for approximately $230 million, aimed at bolstering its molecular diagnostics capabilities. While this acquisition is expected to have a near-term dilutive impact on EPS, it aligns with BD's strategy of expanding its product portfolio. Investors should note the company's continued investment in R&D and the increasing trend of share-based compensation, which is impacting profitability. Overall, the quarter reflects strong operational execution and strategic moves to position the company for future growth, despite potential headwinds from competition and regulatory environments.

Key Highlights

1Revenue increased by 10% to $1.41 billion for the quarter ended December 31, 2005, compared to the prior year period.
2Net income rose to $217.9 million ($0.85 diluted EPS) from $195.4 million ($0.75 diluted EPS) in the comparable prior year quarter.
3All three business segments (Medical, Diagnostics, Biosciences) experienced revenue growth, with Medical showing an 11% increase.
4Operating income improved significantly, with total segment operating income up by approximately 26% year-over-year.
5The company entered into an agreement to acquire GeneOhm Sciences for $230 million (plus potential contingent payments) to expand its molecular diagnostics offerings.
6Share-based compensation expense increased significantly to $34.6 million from $11.6 million in the prior year quarter.
7Cash and equivalents increased by $126 million during the quarter, reaching $1.17 billion.

BECTON DICKINSON & CO Quarterly Report for Q1 Ended Dec 31, 2005

Summary

Key Highlights

Frequently Asked Questions